Pharma, Startups

Effector Therapeutics bumps up Series B to $56M

Effector’s small molecule drugs are meant to control the gene expression of cancers, and potentially other serious diseases.

moneySan Diego-based Effector Therapeutics – which is developing a new class of small molecule drugs for cancer treatment – just added $16 million to its Series B round, first announced in December, bringing the total to $56 million. These drugs are meant to control the gene expression of cancers, and potentially other serious diseases.

The new funding comes from Sectoral Asset Management. In total, the startup has raised about $111 million. The company’s underlying research comes from University of California, San Francisco.

Effector’s lead compound is an oral MNK1 and MNK2 inhibitor, called eFT508, which is being studied in a Phase 1/2 trial with patients that have advanced solid tumors. The company expects to file a second IND for the drug this year to study its efficacy in lymphoma as well. Effector also plans to announce a second drug candidate later this year.

The company says that eFT508 can regulate a number of cancer-driving and immune-signaling pathways – designed to restore translational control to stop disease progression.

Topics